natgillin/translations-raw huggingface dataset:
Not known (frequency cannot be estimated from the available data):
Pogostnost neznana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov)
In clinical trials this was not seen.
V kliničnih preskušanjih tega niso opazili.
I, and patients were assessed about 8 months later.
Bolnike so nato pregledali 8 mesecev kasneje.
It is comprised of two non-covalently linked subunits.
Sestavljen je iz dveh nekovalentno povezanih podenot.
Your medicine will be injected by a doctor or a nurse.
Zdravilo vam bo injiciral zdravnik ali medicinska sestra.
The elimination halflife was 22 ± 9 hours.
Razpolovni čas je bil 22 ± 9 ur.
This may lead to acute symptoms, which depend on the anatomical location of the tissue.
To lahko povzroči akutne simptome, ki so odvisni od anatomske lokacije tkiva.
It is important to note that the microbiological safety depends on the aseptic conditions during the preparation of the solution.
Mikrobiološka varnost je odvisna od aseptičnih pogojev med pripravo raztopine.
The reporting rate is classified as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data).
Njihova pogostnost je razvrščena kot zelo pogosti (≥1/10); pogosti (≥1/100 do < 1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The most commonly reported adverse reactions are nausea and headache, occurring in approximately 11%, and 6% of patients, respectively.
Neželena učinka, o katerih se največkrat poroča, sta navzea in glavobol, ki se pojavita pri približno 11 % oziroma 6 % bolnikov.
The median follow-up was 6.5 years (4.5 to 7.6 years).
Mediano trajanje spremljanja je bilo 6,5 leta (od 4,5 do 7,6 leta).
Data on exposure above the recommended dose is limited to clinical studies and a special treatment program.
Podatki o izpostavljenosti večjemu odmerku, kot je priporočen, so omejeni na klinično preskušanje in poseben program zdravljenja.
Overall, 48/51 patients (94%) had no evidence of cancer recurrence, 1 patient had possible cancer recurrence (although it was not clear whether this patient had a true recurrence or persistent tumour from the regional disease noted at the start of the original study), and 2 patients could not be assessed.
V celoti 48/51 bolnikov (94 %) ni imelo znakov ponovitve raka, 1 bolnik je imel možno ponovitev raka (čeprav ni bilo jasno, ali je imel ta bolnik resnično ponovitev ali obstoječ tumor zaradi regionalnega obolenja, ki so ga opazili na začetku izvorne študije), 2 bolnikov pa ni bilo mogoče oceniti.
Use aseptic technique.
Uporabite aseptično tehniko
The long term follow-up data in ESTIMABL1 and HiLo confirmed similar outcomes for patients in all four treatment groups.
Podatki dolgoročnega spremljanja v študijah ESTIMABL1 in HiLo so potrdili podobne izide pri bolnikih v vseh štirih terapevtskih skupinah.
The median follow-up was 5.4 years (0.5 to 9.2 years).
Mediano trajanje spremljanja je bilo 5,4 leta (od 0,5 do 9,2 leta).
Analyses of T3 patients and N1 patients showed that these subgroups had equally good ablation success rates as did lower-risk patients.
Analize bolnikov T3 in bolnikov N1 so pokazale, da imata ti dve podskupini enako dobro uspešnost ablacije kot bolniki z manjšim tveganjem.
Do not take Thyrogen if you are pregnant.
Ne jemljite zdravila Thyrogen, če ste noseči.
Administration within 3 hours after reconstitution.
Uporabite v 3 urah po rekonstituciji.
Non-clinical data are limited, but reveal no special hazard for humans from use of Thyrogen.
Neklinični podatki so omejeni, vendar ne kažejo posebnega tveganja za človeka pri uporabi zdravila Thyrogen.
Your doctor will decide if you belong to a specific group of patients for which pre-treatment with corticosteroids is to be considered (for example, if you have secondary cancer growths in your brain or spinal cord).
Vaš zdravnik se bo odločil, ali sodite v posebno skupino bolnikov, pri katerih je treba razmisliti o zdravljenju s kortikosteroidi (če imate na primer sekundarne rakave zasevke v možganih ali hrbtenjači).
Diagnostic use
Diagnostična uporaba
In both studies, patients were randomised to 1 of 4 treatment groups: Thyrogen + 30 mCi
V obeh študijah so bolnike naključno razporedili v eno od 4 terapevtskih skupin: Thyrogen + 30 mCi
When the powder is dissolved the total volume in the vial is 1.2 ml.
Ko je prašek raztopljen, je skupni volumen v viali 1,2 ml.
Pre-therapeutic stimulation
Predterapevtska stimulacija
45, 51, 68, 74, 76 and 80 New York Avenue Framingham, MA 01701
45,51, 68,74,76 and 80 New York Avenue Framingham, MA 01701Združene države Amerike
Results from controlled trials indicate no difference in the safety and efficacy of Thyrogen between adult patients less than 65 years and those greater than 65 years of age, when Thyrogen is used for diagnostic purposes.
Rezultati kontroliranih preskušanj kažejo, da ni razlike v varnosti in učinkovitosti zdravila Thyrogen med odraslimi bolniki, starimi manj kot 65 let, in bolniki, starimi nad 65 let, če se zdravilo Thyrogen uporablja za diagnostične namene.
The tables below provide long term follow up information for the ESTIMABL1 and HiLo studies
Spodnje preglednice prikazujejo podatke o dolgoročnem spremljanju v študijah ESTIMABL1 in HiLo
For the ESTIMABL1 study, 726 (97%) of the original 752 patients were followed up for disease recurrence.
V študiji ESTIMABL1 so glede ponovitve bolezni spremljali 726 (97 %) od prvotnih 752 bolnikov.
Patients were still considered to be successfully ablated if there was no visible thyroid bed uptake on the scan, or if visible, uptake was less than 0.1%.
Ablacija je bila pri bolnikih še vedno obravnavana kot uspešna, če pri scintigrafiji ni bilo opaziti vidnega privzema ležišča ščitnice, ali če je bilo vidno, je bil privzem manjši od 0,1 %.
In patients with significant renal impairment the activity of radioiodine should be carefully selected by the nuclear medicine physician.
Pri bolnikih s pomembno ledvično okvaro mora aktivnost radioaktivnega joda previdno odmeriti zdravnik s področja nuklearne medicine.
• pain (including pain at the site of metastases (secondary cancer growths))
• bolečina (vključno z bolečino na mestu metastaz (sekundarni rakavi zasevki))
Total number of patients with recurrence (5.4 years) Low activity RAI (1.1 GBq) High activity RAI (3.7 GBq)
Celotno število bolnikov s ponovitvijo (5,4 leta) Nizka aktivnost RAI (1,1 GBq) Visoka aktivnost RAI (3,7 GBq)
• if you are allergic to bovine or human thyroid stimulating hormone (TSH) or any of the other ingredients of this medicine (listed in section 6).
• če ste alergični na goveji ali humani ščitnico stimulirajoči hormon (TSH) ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Post-treatment scanning may be delayed a few days to allow background radioactivity to decline.
Pregled po zdravljenju lahko za nekaj dni prestavite, da se izvorna radioaktivnost zmanjša.
For the HiLo study, 434 (99%) of the original 438 patients were followed up for disease recurrence.
V študiji HiLo so glede ponovitve bolezni spremljali 434 (99 %) od prvotnih 438 bolnikov.
Effect on tumour growth and/or size
Učinek na rast tumorja in/ali njegovo velikost:
Your child's doctor will help you decide if Thyrogen should be given to your child.
Zdravnik vašega otroka vam bo pomagal pri odločitvi, ali naj vaš otrok prejme zdravilo Thyrogen.
Genzyme Europe B.V., Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands
Genzyme Europe B.V., Paasheuvelweg 25, 1105 BP Amsterdam, Nizozemska.
Due to a lack of data on the use of Thyrogen in children, Thyrogen should be given to children only in exceptional circumstances.
Zaradi pomanjkanja podatkov o uporabi zdravila Thyrogen pri otrocih lahko zdravilo Thyrogen dajemo otrokom samo v izrednih okoliščinah.
Thyrogen contains sodium, see section 2.
Zdravilo Thyrogen vsebuje natrij, glejte poglavje 2.
Swirl the contents of the vial gently until all material is dissolved.
Vsebino viale nežno obračajte, da se ves prašek raztopi.
No dose adjustment is necessary in elderly (see section 4.4).
Pri starejših bolnikih odmerka ni treba prilagajati (glejte poglavje 4.4).
Formal interaction studies between Thyrogen and other medicinal products have not been performed.
Formalne študije interakcij med zdravilom Thyrogen in drugimi zdravili niso bile opravljene.
In one of the studies, two dose regimens were examined: 0.9 mg intramuscular every 24 hours for two doses (0.9 mg x 2) and 0.9 mg intramuscular every 72 hours for three doses (0.9 mg x 3).
V eni izmed študij so preverili dve shemi odmerjanja: 0,9 mg intramuskularno vsakih 24 ur za dva odmerka (0,9 mg x 2) in 0,9 mg intramuskularno vsakih 72 ur za tri odmerke (0,9 mg x 3).
• if you have reduced liver function; you should still be able to receive Thyrogen.
• če imate zmanjšano delovanje jeter; kljub temu lahko prejemate zdravilo Thyrogen.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
V posamezni skupini pogostnosti so neželeni učinki navedeni po padajoči resnosti.
High activity dose RAI (3.7 GBq)
Visoka aktivnost RAI (3,7 GBq)
The occurrence of antibodies which could interfere with endogenous TSH assays performed during regular follow-ups cannot be excluded.
Pojava protiteles, ki bi lahko motila določanje endogenega TSH, ki se izvaja med rednimi pregledi, ne moremo izključiti.
Recurrence rate (3 years)
Delež ponovitev (3 leta)
Your doctor will determine the exact activity of radioiodine to use for radioiodine imaging, taking into consideration the fact that you continue to take thyroid hormones.
Vaš zdravnik bo določil natančno aktivnost radioaktivnega joda za slikanje ob upoštevanju dejstva, da boste nadaljevali z jemanjem ščitničnih hormonov.
The adverse reactions mentioned in the table, combine adverse reactions in the six prospective clinical trials (N=481) and undesirable effects that have been reported to Genzyme after licensure of Thyrogen.
Neželeni učinki, navedeni v preglednici, združujejo neželene učinke iz šestih prospektivnih kliničnih preskušanj (N = 481) in neželene učinke, ki so jih poročali družbi Genzyme po pridobitvi dovoljenja za promet za zdravilo Thyrogen.
Do not use this medicine if you notice foreign particles, cloudiness or discoloration.
Ne uporabljajte tega zdravila, če opazite, da vsebuje tuje delce, je motno ali razbarvano.
If the metastases are present in narrow spaces e.g. intracerebral (in the brain) or in the spinal cord, patients could experience symptoms which can occur quickly such as partial paralysis affecting one side of the body (hemiparesis), breathing problems or loss of vision.
Če so zasevki prisotni v ozkih prostorih, npr. intracerebralno (v možganih) ali v hrbtenjači, lahko pri bolnikih pride do simptomov, ki se lahko pojavijo hitro, kot je delna paraliza, ki prizadene eno stran telesa (hemipareza), težave z dihanjem ali izguba vida.
The presence of Tg autoantibodies can be expected in 18-40% of patients with differentiated thyroid cancer and may cause false negative serum Tg measurements.
Prisotnost avtoprotiteles Tg lahko pričakujemo pri 18 - 40 % bolnikov z diferenciranim rakom ščitnice, to pa lahko povzroči lažno negativne meritve ravni Tg v serumu.
After injection, the mean peak (Cmax) level obtained was 116 ± 38 mU/l and occurred approximately 13 ± 8 hours after administration.
Po injiciranju je znašala povprečna največja koncentracija (Cmax) 116 ± 38 milienot/l in se je pojavila približno 13 ± 8 ur po dajanju.
Three patients in clinical trials and one patient in the special treatment program experienced symptoms after receiving Thyrogen doses higher than those recommended.
Pri treh bolnikih v kliničnih preskušanjih in pri enem bolniku pri posebnem programu zdravljenja so se pojavili simptomi po tem, ko so prejemali višje odmerke zdravila Thyrogen, kot je bilo priporočeno.
Pregnancy Animal reproduction studies have not been conducted with Thyrogen.
Nosečnost Študije razmnoževanja pri živalih z zdravilom Thyrogen niso bile opravljene.
In the absence of compatibility studies, this medicinal product must not be administered as a mixture with other medicinal products in the same injection.
Zaradi pomanjkanja študij kompatibilnosti zdravila ne smemo mešati z drugimi zdravili v isti injekciji.
Low activity dose RAI (1.1 GBq)
Nizka aktivnost RAI (1,1 GBq)
In clinical trials with thyrotropin alfa, which produces a short-term increase in serum TSH levels, no case of tumour growth has been reported.
V kliničnih preskušanjih s tirotropinom alfa, ki povzroči kratkoročno zvišanje ravni TSH v serumu, ne poročajo o nobenem primeru rasti tumorjev.
It is unknown whether thyrotropin alfa /metabolites are excreted in human milk.
Ni znano, ali se tirotropin alfa/presnovki izločajo v materino mleko.
HR: 1.62 [95% CI 0.67 - 3.91], p=0.28
ROg: 1,62 [95 % IZ 0,67-3,91], p=0,28
HR: 1.10 [95% CI 0.47 - 2.59]; p=0.83
ROg: 1,10 [95 % IZ 0,47-2,59], p=0,83
The powder for solution for injection has to be reconstituted with water for injection.
Prašek za raztopino za injiciranje mora biti rekonstituiran z vodo za injekcije.
TSH decreased
Preiskave znižan TSH
Cardiac disorders palpitations
Srčne bolezni palpitacije
Thyrogen (N=374) THW (N=378)
Zdravilo Thyrogen (N = 374)
Thyrogen may reduce the ability to drive or use machines, since dizziness and headaches have been reported.
Zdravilo Thyrogen lahko zmanjša sposobnost upravljanja vozil in strojev, ker so poročali o omotici in glavobolih.
Patients studied were adults (>18 years), with newly diagnosed differentiated papillary or follicular thyroid carcinoma, including papillary-follicular variant, characterised, principally (54 of 60), as T1-T2, N0-N1, M0 (TNM classification).
V študijo vključeni bolniki so bili odrasli (>18 let), pri katerih je bil pred kratkim diagnosticiran diferencirani papilarni ali folikularni karcinom ščitnice, vključno s papilarnofolikularno različico, označen predvsem (54 od 60) kot T1-T2, N0-N1, M0 (TNM klasifikacija).
Infections and infestations influenza
Infekcijske in parazitske bolezni gripa
Do not use Thyrogen:
Ne jemljite zdravila Thyrogen:
Thyrogen does not contain preservatives.
Zdravilo Thyrogen ne vsebuje konzervansov.
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
A. PROIZVAJALEC BIOLOŠKE UČINKOVINE IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ
The pH of the Thyrogen solution is approximately 7.0.
Vrednost pH raztopine zdravila Thyrogen je približno 7,0.
There are no studies of alternative dose schedules of Thyrogen in patients with ESRD to guide dose reduction in this population.
Študij alternativnih režimov odmerjanja zdravila Thyrogen pri bolnikih z ESRD, ki bi podali navodila za zmanjšanje odmerka pri tej populaciji, niso izvajali.
Breast-feeding should only be resumed following advice from your doctor.
Z dojenjem nadaljujte samo po posvetovanju z zdravnikom.
The use of Thyrogen in patients with reduced liver function does not warrant special considerations.
Uporaba zdravila Thyrogen pri bolnikih z zmanjšanim jetrnim delovanjem ne zahteva posebnih ukrepov.
In summary, these studies support the efficacy of low activity radioiodine plus thyrotropin alpha (with reduced radiation exposure).
Če povzamemo, sta ti dve študiji pokazali učinkovitost zdravljenja z nizko aktivnostjo radioaktivnega joda v kombinaciji s tirotropinom alfa (z zmanjšano izpostavljenostjo sevanju).
• if you have reduced kidney function and he will decide how much radioiodine to give you.
• če imate zmanjšano delovanje ledvic, da se odloči, koliko radioaktivnega joda boste prejeli,
Thyrogen-stimulated thyroglobulin levels were above 2 ng/ml in all 35 patients, whereas, thyroglobulin on THST was above 2 ng/ml in 79% of these patients.
Z zdravilom Thyrogen stimulirane ravni tiroglobulina so bile nad 2 ng/ml pri vseh 35 bolnikih, medtem ko je bil tiroglobulin pri THST nad 2 ng/ml pri 79 % teh bolnikov.
The cDNAs encode for an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites, and a beta subunit of 118 residues containing one N-linked glycosylation site.
cDNA kodira za alfa podenoto iz 92 aminokislinskih ostankov z dvema N-glikozilacijskima mestoma in za beta podenoto iz 118 ostankov z enim N-glikozilacijskim mestom.
If you are given more Thyrogen than you should receive Patients who accidentally received too much Thyrogen have reported nausea, weakness, dizziness, headache, vomiting and hot flashes.
Če ste dobili večji odmerek zdravila Thyrogen, kot bi smeli Bolniki, ki so nenamerno prejeli prevelik odmerek zdravila Thyrogen, so poročali o, oslabelosti, omotičnosti, glavobolu, bruhanju in vročinskih oblivih.
Do not use this medicine after the expiry date which is stated on the label after “EXP”.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
This was thought to be related to the elevated thyroid stimulating hormone (TSH) levels over a longer period.
Menijo, da je to povezano s zvišanjem ravni ščitnico stimulirajočega hormona (TSH) skozi daljši čas.
One of the effects is that it stimulates any remaining thyroid tissue to take up iodine which is important for radioiodine imaging.
Eden od učinkov je stimuliranje ostankov ščitničnega tkiva k privzemu joda, ki je pomemben za slikanje z radioaktivnim jodom.
Diagnostic scanning should be performed 48 to 72 hours after the radioiodine administration (72 to 96 hours after the final injection of Thyrogen).
Diagnostični pregled je treba opraviti 48 do 72 ur po dajanju radioaktivnega joda (72 do 96 ur po zadnji injekciji zdravila Thyrogen).
Use of Thyrogen with Tg testing in follow up of post-thyroidectomy well differentiated thyroid cancer patients should be in accordance with official guidelines.
Uporaba zdravila Thyrogen z testiranjem Tg za spremljanje posttiroidektomijskih bolnikov z dobro diferenciranim rakom ščitnice mora biti v skladu z uradnimi smernicami.
There is a theoretical possibility that Thyrogen, like thyroid hormone withdrawal, may lead to stimulated tumour growth.
Obstaja teoretična možnost, da zdravilo Thyrogen, tako kot odstranitev tiroidnega hormona, povzroči stimulirano rast tumorjev.
Each vial of Thyrogen is for single use only.
Vsaka viala zdravila Thyrogen je samo za enkratno uporabo.
Your doctor or nurse will inject 1.0 ml of the Thyrogen solution.
Vaš zdravnik ali medicinska sestra bo injiciral/-a 1,0 ml raztopine zdravila Thyrogen.
What Thyrogen is and what it is used for
Kaj je zdravilo Thyrogen in za kaj ga uporabljamo
• Hypersensitivity to bovine or human thyroid stimulating hormone or to any of the excipients listed in section 6.1.
• Preobčutljivost za ščitnico stimulirajoči hormon govejega ali humanega izvora ali katero koli pomožno snov, navedeno v poglavju 6.1.
• if you have kidney disease that requires dialysis and he will decide how much Thyrogen to give to you as you may have more chance of experiencing headache and nausea.
• če imate bolezen ledvic, zaradi katere je potrebna dializa, da se odloči o količini zdravila Thyrogen, ki jo bo odmeril, saj imate večjo možnost, da se pojavita glavobol ali slabost,
Data on radioiodine kinetics indicate that the clearance of radioiodine is approximately 50% greater while euthyroid than during the hypothyroid state when renal function is decreased, thus resulting in less radioiodine retention in the body at the time of imaging.
Podatki o kinetiki radioaktivnega joda kažejo, da je pri zmanjšanem ledvičnem delovanju očistek radioaktivnega joda v evtirotičnem stanju približno 50 % večji kot v hipotirotičnem stanju, kar vodi k zmanjšanemu zadrževanju radioaktivnega joda v telesu v času scintigrafije.
One additional patient enrolled in a clinical trial experienced symptoms after receiving Thyrogen intravenously.
Še pri enem dodatnem bolniku, ki je bil vključen v klinično preskušanje, so se simptomi pojavili po prejemu zdravila Thyrogen intravensko.
Pack sizes: one or two vials of Thyrogen per carton.
Velikost pakiranja: ena ali dve viali zdravila Thyrogen na škatlico.
Other medicines and Thyrogen Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
This factor should be considered when selecting the activity of radioiodine for use in radioiodine imaging.
Ta dejavnik je potrebno upoštevati pri določanju aktivnosti radioaktivnega joda za uporabo pri scintigrafiji z radioaktivnim jodom.
The Thyrogen solution should be injected within three hours, however the Thyrogen solution will stay chemically stable for up to 24 hours, if kept in a refrigerator (between 2°C and 8°C).
Raztopina zdravila Thyrogen ostane kemijsko stabilna do 24 ur, če jo shranjujete v hladilniku (med 2 °C in 8 °C).
However if your thyroid gland has not been removed completely and you are also suffering from heart disease, your doctor will help you decide if Thyrogen should be given to you.
Če vaša žleza ščitnica ni bila povsem odstranjena in imate hkrati srčno obolenje, vam bo zdravnik svetoval ali naj prejemate zdravilo Thyrogen.
What you need to know before you use Thyrogen
Kaj morate vedeti, preden boste uporabili zdravilo Thyrogen
The main objective of the follow-up study was to confirm the status of thyroid remnant ablation by using Thyrogen-stimulated radioiodine static neck imaging after a median follow-up of 3.7 years (range 3.4 to 4.4 years) following radioiodine ablation.
Glavni cilj spremljevalne študije je bil potrditi stanje ablacije tiroidnih ostankov z uporabo statične scintigrafije vratu z radioaktivnim jodom, stimulirane z zdravilom Thyrogen, po mediani spremljanja 3,7 let (razpon 3,4 do 4,4 leta) po ablaciji z uporabo radioaktivnega joda.
OUTER CARTON - PACK OF 1 VIAL OUTER CARTON - PACK OF 2 VIALS
PODATKI NA ZUNANJI OVOJNINI ZUNANJA OVOJNINA - 1 VIALA ZUNANJA OVOJNINA - 2 VIALI
This may lead to increased risk of headache and nausea.
To lahko povzroči zvečano tveganje glavobola in navzee.
Two patients had nausea after 2.7 mg IM dose, and in one of these patients nausea was also accompanied by weakness, dizziness and headache.
odmerka 2,7 mg pojavila navzea in pri enem od teh bolnikov so se poleg navzee pojavili še šibkost, omotica in glavobol.
These reactions consisted of urticaria, rash, pruritus, flushing and respiratory signs and symptoms.
Med te pojave spadajo urtikarija, izpuščaj, pruritus, vročinski oblivi ter respiratorni znaki in simptomi.
Diagnostic scintigraphy should be performed 48 to 72 hours following radioiodine administration, whereas post-ablation scintigraphy may be delayed additional days to allow background activity to decline.
Diagnostično scintigrafijo izvršimo 48 ali 72 ur po prejetju radioaktivnega joda, medtem ko lahko scintigrafijo po ablaciji odložimo za nekaj dni, da se zmanjša izvorna aktivnost.
The standard approach to achieve elevated TSH levels has been to withdraw patients from thyroid hormone suppression therapy (THST), which usually causes patients to experience the signs and symptoms of hypothyroidism.
Standardni pristop za zvišanje ravni TSH je prenehanje z zdravljenjem s hormonsko supresivno terapijo (THST) pri bolnikih, pri katerih ponavadi povzroči znake ali simptome hipotiroidizma.
This medicinal product contains less than 1 mmol sodium (23 mg) per injection, i.e. essentially ‘sodiumfree'.
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na injekcijo, kar v bistvu pomeni ‘brez natrija'.
Two large prospective randomised studies, the HiLo study (Mallick) and the ESTIMABL1 study (Schlumberger), compared methods of thyroid remnant ablation in patients with differentiated thyroid cancer who had been thyroidectomised.
V dveh velikih prospektivnih, randomiziranih študijah - študiji HiLo (Mallick) in študiji ESTIMABL (Schlumberger) - so primerjali metode ablacije tiroidnih ostankov pri bolnikih z diferenciranim rakom ščitnice, katerim so odstranili ščitnico.